PHASEBIO PHARMACEUTICALS INC (PHAS) Stock Analyst Ratings
USA - NASDAQ:PHAS - US7172241090 - Common Stock
0.0701 USD
-0.02 (-26.21%)
0.0533 USD
-0.02 (-23.97%)
ChartMill assigns a Buy % Consensus number of 46% to PHAS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.02. This target is 1355.06% above the current price.
PHAS was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about PHAS.
In the last month the buy percentage fell by 30 points. So the trust of analysts is decreasing.
PHAS was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-10-24 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-09-28 | William Blair | Downgrade | Outperform -> Market Perform |
| 2022-09-28 | Needham | Downgrade | Buy -> Hold |
| 2022-08-15 | Needham | Maintains | Buy |
| 2021-06-17 | Needham | Maintains | Buy |
| 2021-03-16 | Needham | Maintains | Buy |
PHASEBIO PHARMACEUTICALS INC / PHAS FAQ
Can you provide the average price target for PHASEBIO PHARMACEUTICALS INC stock?
7 analysts have analysed PHAS and the average price target is 1.02 USD. This implies a price increase of 1355.06% is expected in the next year compared to the current price of 0.0701.
What is the consensus rating for PHAS stock?
The consensus rating for PHASEBIO PHARMACEUTICALS INC (PHAS) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.